Literature DB >> 29532611

The impacts of pretreatment circulating eosinophils and basophils on prognosis of stage Ⅰ-Ⅲ colorectal cancer.

Yisheng Wei1,2, Xiao Zhang1, Guoying Wang3, Yaguang Zhou1, Minrui Luo1, Shan Wang4, Chuyuan Hong1.   

Abstract

AIM: The effects of circulating eosinophils and basophils on cancer survival are unclear. Here, we aimed to explore the impacts of eosinophils and basophils on prognosis of stage I-III colorectal cancer (CRC) patients.
METHODS: From February 2003 to March 2013, 569 stage I-III CRC patients were enrolled in this retrospective study. The associations between pretreatment circulating eosinophils, basophils and CRC overall survival (OS), disease-free survival (DFS) were investigated. Moreover, the prognostic value of combined eosinophils/basophils and neutrophil to lymphocyte ratio (NLR)/platelet to lymphocyte ratio (PLR) was investigated.
RESULTS: Kaplan-Meier methods showed the associations of eosinophils < 0.095 × 109 /L and shorter OS (P < 0.0001), eosinophils < 0.055 × 109 /L and shorter DFS (P < 0.0001), basophils < 0.015 × 109 /L and shorter OS (P = 0.001), basophils < 0.015 × 109 /L and shorter DFS (P = 0.005). Cox regression model showed that eosinophils < 0.095 × 109 /L (hazard ratio [HR], 1.723; 95% confidence intervals [CI] = 1.177-2.523) and basophils < 0.015 × 109 /L (HR, 1.714; 95% CI = 1.152-2.548) were independent prognostic factors for OS, and eosinophils < 0.055 × 109 /L (HR, 2.309; 95% CI = 1.587-3.361) and basophils < 0.015 × 109 /L (HR, 1.397; 95% CI = 1.003-1.945) were independent prognostic factors for DFS, respectively. The combined eosinophil-PLR (HR, 2.611; 95% CI = 1.328-5.130) and basophil-PLR (HR, 2.520; 95% CI = 1.240-5.123) were the independent prognostic factors for OS. The combined eosinophil-NLR (HR, 2.770; 95% CI = 1.528-5.019) and eosinophil-PLR (HR, 4.788; 95% CI = 2.458-9.329) were the independent prognostic factors for DFS.
CONCLUSION: Pretreatment circulating eosinophils < 0.095 × 109 /L/0.055 × 109 /L and circulating basophils < 0.015 × 109 /L have significant impacts on prognosis of stage I-III CRC patients.
© 2018 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  basophil; colorectal cancer; eosinophil

Mesh:

Substances:

Year:  2018        PMID: 29532611     DOI: 10.1111/ajco.12871

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  23 in total

1.  Prognostic value of pretreatment circulating basophils in patients with glioblastoma.

Authors:  Lingnan Zheng; Min Yu; Shuang Zhang
Journal:  Neurosurg Rev       Date:  2021-03-25       Impact factor: 3.042

2.  Immune System in Action.

Authors:  Bettzy Stephen; Joud Hajjar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Associations of Complete Blood Count Parameters with Disease-Free Survival in Right- and Left-Sided Colorectal Cancer Patients.

Authors:  Alhasan Alsalman; Mohammad A Al-Mterin; Ala Abu-Dayeh; Ferial Alloush; Khaled Murshed; Eyad Elkord
Journal:  J Pers Med       Date:  2022-05-18

4.  Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer.

Authors:  Agreen Hadadi; Katherine Er Smith; Limeng Wan; Jacqueline R Brown; Greta Russler; Lauren Yantorni; Sarah Caulfield; Jennifer Lafollette; Melvin Moore; Omer Kucuk; Bradley Carthon; Bassel Nazha; Yuan Liu; Mehmet A Bilen
Journal:  Urol Oncol       Date:  2022-04-22       Impact factor: 2.954

5.  Higher Levels of Pre-operative Peripheral Lymphocyte Count Is a Favorable Prognostic Factor for Patients With Stage I and II Rectal Cancer.

Authors:  Ying-Ying Zhang; Wan-Qing Li; Zhen-Fa Li; Xiao-Hua Guo; Shen-Kang Zhou; Aifen Lin; Wei-Hua Yan
Journal:  Front Oncol       Date:  2019-09-24       Impact factor: 6.244

6.  Circulating basophil count as a prognostic marker of tumor aggressiveness and survival outcomes in colorectal cancer.

Authors:  Qi Liu; Dakui Luo; Sanjun Cai; Qingguo Li; Xinxiang Li
Journal:  Clin Transl Med       Date:  2020-02-10

7.  Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma.

Authors:  Mario Scartozzi; Andrea Casadei-Gardini; Giulia Orsi; Francesco Tovoli; Vincenzo Dadduzio; Caterina Vivaldi; Oronzo Brunetti; Luca Ielasi; Fabio Conti; Giulia Rovesti; Laura Gramantieri; Mario Domenico Rizzato; Irene Pecora; Antonella Argentiero; Federica Teglia; Sara Lonardi; Francesca Salani; Alessandro Granito; Vittorina Zagonel; Giorgia Marisi; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Francesca Benevento; Alessandro Cucchetti; Fabio Piscaglia; Stefano Cascinu
Journal:  Target Oncol       Date:  2020-12       Impact factor: 4.493

Review 8.  The Janus Face of IL-33 Signaling in Tumor Development and Immune Escape.

Authors:  Mi-Ran Choi; Jeffrey A Sosman; Bin Zhang
Journal:  Cancers (Basel)       Date:  2021-06-30       Impact factor: 6.639

9.  Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils.

Authors:  Anm Nazmul H Khan; Tiffany R Emmons; Jerry T Wong; Emad Alqassim; Kelly L Singel; Jaron Mark; Brandon E Smith; Joseph D Tario; Kevin H Eng; Kirsten B Moysich; Kunle Odunsi; Scott I Abrams; Brahm H Segal
Journal:  Cancer Immunol Res       Date:  2020-04-01       Impact factor: 12.020

Review 10.  The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity.

Authors:  Claudia Afferni; Carla Buccione; Sara Andreone; Maria Rosaria Galdiero; Gilda Varricchi; Gianni Marone; Fabrizio Mattei; Giovanna Schiavoni
Journal:  Front Immunol       Date:  2018-11-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.